Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ocunova
Harrisburg, Pennsylvania, United Statesocunova.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Other
01
Overview
Ocunova is developing OCU-001, a repurposed naltrexone-based small‑molecule eye drop for diabetic dry eye syndrome; the company has completed early clinical work showing activity in diabetics with dry eye and is raising capital for a Phase 2/2b efficacy study in dry eye disease, including diabetic dry eye and neurotrophic keratitis.[1][2][4][5][8]
- Therapeutic areas
- Ophthalmology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Penn State College of Medicine / Penn State Medical Center (technology origin and IP licensing)[2][5]Life Sciences Greenhouse of Central Pennsylvania (LSGCP) – seed/early funding partner[2][6][8]Ben Franklin Technology Partners of Central and Northern Pennsylvania – seed/early funding partner[2][5][6][8]
Beyond the preview
Go deeper on Ocunova.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ocunova.